Preimplantation Genetic Testing Market Worth 541.8 Million USD by 2022

Thursday, July 13, 2017 General News
Email Print This Page Comment
Font : A-A+

PUNE, India, July 13, 2017 /PRNewswire/ --

According to a new market research report "Preimplantation Genetic Testing Market

 by Type (Genetic Diagnosis/Genetic Screening), Technology (NGS, PCR, FISH, CGH, SNP), Products & Services, Application (Aneuploidy, Translocations), End User (Fertility Clinics, Research) - Forecast to 2022", published
by MarketsandMarkets™, the Global Preimplantation Genetic Testing Market is projected to reach USD 541.8 Million by 2022 from USD 336.4 Million in 2017, at a CAGR of 10.0%.

     (Logo: http://photos.prnewswire.com/prnh/20160303/792302 )

Browse 85 Market Data Tables and 42 Figures spread through 204 Pages and in-depth TOC on "Preimplantation Genetic Testing Market"

http://www.marketsandmarkets.com/Market-Reports/preimplantation-genetic-testing-market-605.html Early buyers will receive 10% customization on this report

Factors such as the growing rate of infertility across the globe, increasing public-private investments in the field of preimplantation genetic testing, rising number of fertility clinics worldwide, technological advancements in the field of genetic analysis, and high risk of chromosomal abnormalities in the fetus with increasing maternal age are driving the growth of this market.

The preimplantation genetic screening segment accounted for the largest share of the market in 2016 

By type, the preimplantation genetic screening segment accounted for the largest share of the market. The large share of this segment can primarily be attributed to the decrease in female fertility (due to rising maternal age), increasing prevalence of genetic disorders in offspring, and benefits of PGS, such as increased chances of healthy pregnancy across all age groups, better implantation rate, reduced risks of miscarriage, reduced IVF cycle time, and comprehensive analysis of all 24 chromosome types.

Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=605

By application, the aneuploidy segment is expected to be the fastest growing segment in the forecast period 

The aneuploidy segment is expected to grow at the fastest CAGR. Growth of this segment can be attributed to the increasing maternal age, rising incidence of aneuploidy disorders, and strategic initiatives by key players to provide technologically advanced PGS products for aneuploidy screening.

Aneuploidy screening has been reported to increase the chance of successful embryo implantation, decreases miscarriage rate, and reduce the chance of having a child with a chromosome abnormality).

Talk To Our Research Analysts: http://www.marketsandmarkets.com/speaktoanalyst.asp?id=605

North America dominated the market in 2016 

Geographically, the Preimplantation Genetic Testing Market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America accounted for the largest share of the market in 2016, followed by Europe. Rising number of IVF procedures (with decreasing fertility rates), significant adoption of genomic techniques, ongoing trend of replacing traditional genomic technologies with advanced and innovative genetic techniques (such as FISH and NGS), and increasing private-public funding to develop and commercialize novel PGS & PGD procedures are the key factors that account for the larger share of the Preimplantation Genetic Testing Market in North America.

As of 2016, the major product manufacturers operating in the global Preimplantation Genetic Testing Market included Illumina, Inc. (U.S.), CooperSurgical, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Abbott Laboratories (U.S.), Natera, Inc. (U.S.), Rubicon Genomics, Inc. (U.S.), Oxford Gene Technology (U.K.), Yikon Genomics (China), and SciGene Corporation (U.S.), among others. Moreover, as of 2016, major service providers active in the global market included Beijing Genomics Institute (BGI) (China), Good Start Genetics (U.S.), CombiMatrix Corporation (U.S.), Genea Limited (Australia), Invicta Genetics (Poland), and Progenesis (U.S.).

Browse Related Reports: 

NON-INVASIVE PRENATAL TESTING (NIPT) MARKET-By Instruments (Ultrasound, NGS, PCR, Microarray), Consumables, Method (FCMB, cf-DNA), Application (Trisomy, Microdeletion, Genetics, Rh factor) & End User (Hospital, Diagnostic Labs) - Global Forecast to 2021

http://www.marketsandmarkets.com/Market-Reports/non-invasive-prenatal-testing-market-145607690.html

IN VITRO FERTILIZATION (IVF) MARKET-By Product (Incubators, Cryosystem, Sperm Separation System, Cryopreservation Media, Embryo Culture Media), Technology (Pre-Implantation Genetic Diagnosis, Intra-Cytoplasmic Sperm Injection) & End Users - Global Forecast to 2021

http://www.marketsandmarkets.com/Market-Reports/in-vitro-fertilization-market-89198891.html

About MarketsandMarkets™  

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets' flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact: Mr. Rohan MarketsandMarkets™ 701 Pike Street Suite 2175, Seattle, WA 98101, United States Tel: +1-888-600-6441 Email: sales@marketsandmarkets.com

Visit Our Blog@ http://mnmblog.org/market-research/healthcare/biotechnology

Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets

SOURCE MarketsandMarkets



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook